Analysis of the data obtained from the Oncomine database revealed that the level of BUB1 expression was significantly high in the central nervous system, bladder, cervical, brain, ovarian, breast, gastric, colorectal, esophageal, head, pancreatic, liver, neck, lung, and prostate, cancers, as well as lymphomas, and sarcoma cancers. Here, BUB1 is linked to lymphoma.